EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Effectiveness of benznidazole in the treatment of Chagas disease in children and adults: a long-term retrospective cohort study

A Rabinovich iD, C Cruz iD, G Moscatelli, S Moroni, N González, J C Ramirez, F Garcia-Bournissen, G Ballering, H Freilij, J Altcheh iD

Antimicrobial Agents and Chemotherapy · 2026

DOI: 10.1128/aac.00203-26 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von A Rabinovich und 9 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Parasitología and Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas (IMIPP), CONICET-GCBA, Hospital de Niños Rica…. Hauptthemen laut MEDLINE: Nitroimidazoles, Chagas Disease, Trypanocidal Agents, Trypanosoma cruzi. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chagas disease, caused by Trypanosoma cruzi , is endemic to the Americas but has spread worldwide due to migration. Benznidazole is effective, but long-term follow-up efficacy studies are scarce and include only small numbers of patients. We analyzed data from a retrospective cohort of Chagas disease patients treated with benznidazole at a large tertiary center in Argentina (1980–2019). Treatment response was assessed through clinical, parasitological, and serological follow-up. Parasitemia was evaluated by direct visualization or PCR. Among 567 treated patients, 464 met selection criteria, including 411 children (median age: 46 months, IQR: 9.5–124 months) and 53 adults (median age: 26 years, IQR: 20–34 years). At diagnosis, 11/411 (2.68%) children and 1/53 (1.9%) adults were symptomatic; all improved after treatment. Baseline parasitemia was detected in 289/445 (64.94%) of patients, and 279/289 (96.54%) had parasitological follow-up for at least 3 years. Median benznidazole dose was 6.6 mg/kg/day in children and 5.6 mg/kg/day in adults, with treatment durations of 8 weeks and 31 days, respectively. All patients cleared parasitemia at treatment completion. Median serological follow-up was 4.8 years for children and 2.8 years for adults. At 1-year follow-up, 38.8% of patients showed >20% reduction in T. cruzi antibody titers, and 29.8% achieved seronegativity, with younger patients converting faster ( P < 0.01). In this Argentinian cohort, Benznidazole achieved sustained parasitemia clearance and declining antibody titers, supporting early treatment initiation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NitroimidazolesChagas DiseaseTrypanocidal AgentsTrypanosoma cruziHumansRetrospective StudiesFemaleAdultMaleChildParasitemiaChild, PreschoolYoung AdultTreatment OutcomeInfantArgentina

Stichwörter der Autor:innen

Chagas diseaseTrypanosoma cruziadultsbenznidazolechildrentreatment

Substanzen

NitroimidazolesbenzonidazoleTrypanocidal Agents

Autor:innen und Institutionen

  • Servicio de Parasitología and Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas (IMIPP), CONICET-GCBA, Hospital de Niños Ricardo Gutierrez, Buenos Aires, Argentina.
  • Division of Clinical Pharmacology and Toxicology, Department of Pediatrics, Sickkids, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
  • Mahidol Oxford Research Unit (MORU), Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Division of Paediatric Clinical Pharmacology, Department of Paediatrics, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.

ORCID-Profile: A Rabinovich, C Cruz, J Altcheh

Förderung

  • Wellcome Trust

Zitieren

APA

Rabinovich, A., Cruz, C., Moscatelli, G., Moroni, S., González, N., Ramirez, J. C., Garcia-Bournissen, F., Ballering, G., Freilij, H., & Altcheh, J. (2026). Effectiveness of benznidazole in the treatment of Chagas disease in children and adults: a long-term retrospective cohort study. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00203-26

Vancouver

Rabinovich A, Cruz C, Moscatelli G, Moroni S, González N, Ramirez JC, et al. Effectiveness of benznidazole in the treatment of Chagas disease in children and adults: a long-term retrospective cohort study. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.00203-26

BibTeX
@article{Rabinovich2026,
  author = {Rabinovich, A and Cruz, C and Moscatelli, G and Moroni, S and González, N and Ramirez, J C and Garcia-Bournissen, F and Ballering, G and Freilij, H and Altcheh, J},
  title = {Effectiveness of benznidazole in the treatment of Chagas disease in children and adults: a long-term retrospective cohort study},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.00203-26}
}
Kostenlos starten →